» Articles » PMID: 38130033

A Cross-sectional Study of MRI Features and the Gut Microbiome in Pediatric-onset Multiple Sclerosis

Abstract

Objective: To identify gut microbiome features associated with MRI lesion burden in persons with pediatric-onset multiple sclerosis (symptom onset <18 years).

Methods: A cross-sectional study involving the Canadian Paediatric Demyelinating Disease Network study participants. Gut microbiome features (alpha diversity, phylum- and genus-level taxa) were derived using 16S rRNA sequencing from stool samples. T1- and T2-weighted lesion volumes were measured on brain MRI obtained within 6 months of stool sample procurement. Associations between the gut microbiota and MRI metrics (cube-root-transformed) were assessed using standard and Lasso regression models.

Results: Thirty-four participants were included; mean ages at symptom onset and MRI were 15.1 and 19.0 years, respectively, and 79% were female. The T1- and T2-weighted lesion volumes were not significantly associated with alpha diversity (age and sex-adjusted p > 0.08). At the phylum level, high Tenericutes (relative abundance) was associated with higher T1 and T2 volumes (β coefficient = 0.25, 0.37) and high Firmicutes, Patescibacteria or Actinobacteria with lower lesion volumes (β coefficient = -0.30 to -0.07). At the genus level, high Ruminiclostridium, whereas low Coprococcus 3 and low Erysipelatoclostridium were associated with higher lesion volumes.

Interpretation: Our study characterized the gut microbiota features associated with MRI lesion burden in pediatric-onset MS, shedding light onto possible pathophysiological mechanisms.

Citing Articles

The Role of the Intestinal Flora and Its Derivatives in Neurocognitive Disorders: A Narrative Review from Surgical Perspective.

Huang J, Qin T, Bo Y, Li Y, Liu R, Yu Y Mol Neurobiol. 2024; 62(2):1404-1414.

PMID: 38985257 PMC: 11772545. DOI: 10.1007/s12035-024-04322-1.

References
1.
Hemond C, Bakshi R . Magnetic Resonance Imaging in Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018; 8(5). PMC: 5932576. DOI: 10.1101/cshperspect.a028969. View

2.
Brownlee W, Altmann D, Prados F, Miszkiel K, Eshaghi A, Wheeler-Kingshott C . Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain. 2019; 142(8):2276-2287. DOI: 10.1093/brain/awz156. View

3.
Dalile B, Van Oudenhove L, Vervliet B, Verbeke K . The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. 2019; 16(8):461-478. DOI: 10.1038/s41575-019-0157-3. View

4.
Waubant E, Chabas D, Okuda D, Glenn O, Mowry E, Henry R . Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol. 2009; 66(8):967-71. DOI: 10.1001/archneurol.2009.135. View

5.
Waters P, Woodhall M, OConnor K, Reindl M, Lang B, Sato D . MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2015; 2(3):e89. PMC: 4370386. DOI: 10.1212/NXI.0000000000000089. View